Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi-Aventis and Novozymes in antibiotic development deal

This article was originally published in Scrip

Executive Summary

Sanofi-Aventis and Novozymes have struck a global licensing agreement to develop and market a potential new antibiotic. The two firms will develop plectasin NZ2114, a drug candidate developed by Novozymes for the treatment of severe infections, such as pneumonia, septicaemia and complicated skin and soft tissue infections. Dr Marc Cluzel, senior vice-president of R&D at Sanofi-Aventis, says that the candidate, from a novel class of antimicrobials, is potentially more active against resistant bacteria than currently available treatments. It is a variant of plectasin, a defensin-type peptide antibiotic, which is active against resistant and sensitive Gram-positive bacteria such as Staphylococci and Streptococci. The French company has an exclusive worldwide licence for the development, registration and commercialisation of the drug. Plectasin NZ2114 is the first drug candidate that Novozymes has outlicensed for further preclinical and clinical development, it says. Financial terms were not disclosed.

You may also be interested in...



Innovation not M&A to drive Bayer growth in LatAm

Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.

2010 Scrip 100 - Is Anvisa a friend of innovators?

A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.

Elan raises $1.5 billion

Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.

Topics

Related Companies

UsernamePublicRestriction

Register

LL038093

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel